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Comparison of Treatment with Corticosteroid Alone vs Corticosteroid and Cyclophosphamide in 
Combination in Patients with MPO-ANCA Positive Necrotizing Crescentic Glomerulonephritis During 5 
Years Follow-up
Syuji Takahira (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350-0495, Japan)
To evaluate the long-term outcome of patients with anti-myeloperioxidase (MPO) anti-neutrophil cytoplasmic 
antibody (ANCA)-associated vasculitis, the impact of addition of an intravenous pulse cyclophosphamide therapy 
to a daily oral corticoid therapy was assessed in 20 patients for 5 years. No patient diagnosed with Wegener's 
granulomatosis was included in this study. Ten patients received corticosteroid treatment alone (OCS group) and 
10 patients were treated with corticosteroid and cyclophosphamide in combination (CYC group). Four patients in 
CYC group, survived their renal function without dialysis. Three of 6 patients that required dialysis therapy, died of 
gastric ulcer, thrombocytopenia probably due to cyclophosphamide, and cardiac failure. Two of 10 patients in OCS 
group did not need dialysis therapy. Five (50%) of these patients died and 3 (30%) received dialysis therapy. Three 
patients died of pulmonary hemorrhage, one died of colon cancer, and one died of cardiac failure. At the diagnosis, 
no significant differences in the levels of serum creatinine and MPO-ANCA titer, sex ratio and ages were observed 
between two groups. However, the retrospective analysis revealed that 1) the patients who survived for 5 years 
without dialysis therapy irrespectively of two types of therapy were all women, 2) the levels of MPO-ANCA at 3 
months after the initiation of treatment were significantly higher (p＜0.05) in patients treated with corticosteroids 
alone than those with combination therapy, and that 3) the scores of renal histopathology (glomerular sclerosis and 
interstitial fibrosis) were significantly higher in patients who failed to survive than those who succeeded to survive 
without dialysis therapy. From these results, it is suggested that the combination therapy with corticosteroids 
and cyclophosphamide might be effective for improvement of life and renal survival of patients with MPO- ANCA-
associated vasculitis. Moreover, the values of MPO-ANCA should be evaluated after the start of the therapy. 
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（PSL）を 0.7 mg/kg経口で連日投与し以後 1週間毎




クロホスファミド 750 mg /回 の投与を 4週毎に施行
した．クレアチニンクリアランスが 30 ml/min以下の
症例では初期投与量を 500 mg/回に減量した．この投
































本は，糸球体半月体形成 (0 to 4)，糸球体硬化 (0 to 4)，
間質の線維化 (0 to 4)，尿細管の萎縮，傷害 (0 to 4)，そ


















Table 1に示す．OCS群は男性 5名，女性 5名で CYC
群は男性 4名，女性 6名であった．OCS群の平均年
齢は 71.4±7.4歳で CYC群の平均年齢は 66.3±1.3歳
であった．血清クレアチニン値は OCS群で 3.3±0.5 
mg/dl，CYC群で 3.7± 1.1 mg/dlであった．MPO-































全例でMPO-ANCA値が 10 IU/ml未満に低下した（Fig. 
3B）．Fig. 3に示した個々の症例のMPO-ANCA値の変
化を Fig. 4に OCS群と CYS群にまとめて示した．両
群の診断時の値は Table 1に示したように OCS群で




された．一方 OCS群でも 3か月目で 15.2±5.1 IU/ml
と治療前と比較し有意に低下したが，CYC群と比較
し有意に高値であった（p＜0.05）．その後 6か月，12
か月目は 12.3±2.3 IU/mlとなり 3年目および 5年目










Table 1. Clinical and histopathological characteristics of 
subjects at biopsy
Fig. 1. Life sur vival cur ve of 2 groups of the patients 
w i t h  M P O - A N C A  p o s i t i v e  n e c r o t i z i n g  c r e s c e n t i c  
glomerulonephritis. Kaplan Meier-survival curve showed the 
time courses of patients who were treated with intravenous 
pulse cyclophosphamide (CYC) and with oral corticosteroids 
(OCS) administration. Open circle represented a survival 
curve of OCS group, and closed circle represented CYC 
group, respectively. There is no significant difference in life 
survival rate on both groups. Abbreviations are the same as 
the following figure legends. 






















Fig. 2. A)Course of individual serum creatinine values over time in OCS group. B) Course of individual serum creatinine values 
over time in CYC group. -○- indicates patients who were not introduced into dialysis therapy. -□- indicates needed dialysis 
therapy. -△- indicates patients who were dead during the study. 
Fig. 3. A) Course of individual MPO-ANCA titers over time in OCS group. B) Course of individual MPO-ANCA titers over time 
in CYC group. -○- indicates patients who were not introduced into dialysis therapy. -□- indicates patients who needed dialysis 
therapy. -△- indicates patients who were dead during the study.
Fig. 4. Changes in mean values of MPO-ANCA in patients 
with CYC (open column) and OCS (closed column) groups 


























































Table 2. Characteristics of patients without dialysis, on 
dialysis and dead at 5 years
Fig. 6. Changes in mean values of MPO-ANCA in three 
groups; death, survival and dialysis. Survival (open column), 
dialysis (hatched column) and non survival (closed column). 
Values are mean＋SE. *p＜0.05 Survival vs dialysis or non 
survival.
Fig. 5. Mean values of the scores of renal histopathology 
in three groups; death, survival and dialysis. Survival (open 
column), dialysis (hatched column) and non survival (closed 
column). Values are mean＋SE. *p＜0.05 Survival vs dialysis 
or non sur vival. GS:glomerular sclerosis. CF:crescent 
























































































腎生検施行時には臨床診断は rapidly progressive 
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